Sarepta Therapeutics (SRPT) Finished Goods (2016 - 2026)

Sarepta Therapeutics has reported Finished Goods for 11 years, with the latest figure at $58.0 million in Q1 2026.

• For the quarter ending Q1 2026, Finished Goods fell 5.54% year-over-year to $58.0 million; the trailing twelve-month figure through Mar 2026 stood at $58.0 million (down 5.54% YoY), and the FY2025 full-year result was $65.3 million, up 38.36% from the prior year.
• Finished Goods for Q1 2026 stood at $58.0 million, down from $65.3 million in the prior quarter.
• The five-year high for Finished Goods was $78.0 million in Q3 2024, with the low at $33.9 million in Q1 2022.
• Average Finished Goods over 5 years is $52.6 million, with a median of $49.3 million recorded in 2022.
• Year-over-year, Finished Goods surged 83.58% in 2022 and fell 23.62% in 2024.
• Tracing SRPT's Finished Goods over 5 years: stood at $38.1 million in 2022, then soared by 62.02% to $61.8 million in 2023, then slipped by 23.62% to $47.2 million in 2024, then jumped by 38.36% to $65.3 million in 2025, then decreased by 11.24% to $58.0 million in 2026.
• The last three Finished Goods figures came in at $58.0 million (Q1 2026), $65.3 million (Q4 2025), and $64.8 million (Q3 2025), per Business Quant data.

Peer Comparison